中國生物科技服務(08037.HK)擬發行1000萬美元換股債 換股價溢價56.25%
格隆匯4月26日丨中國生物科技服務(08037.HK)公佈,於2020年4月24日,公司與配售代理訂立配售協議,公司擬發行1000萬美元可換股債券。每股換股股份1.75港元,較4月24日收市價每股1.12港元溢價約56.25%。在可換股債券所附帶的換股權獲悉數行使時,將配發最多4485.7萬股,相當於公司現有已發行股本約4.63%及經發行換股股份擴大後已發行股本約4.42%。
認購事項所得款項淨額約為7680萬港元,公司擬將所得款項淨額約2100萬港元用於向個人擔保人償還貸款及利息;約3500萬港元用於潛在投資;及其餘結餘約2080萬港元用於研發成本及集團一般營運資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.